The landmark 2020 No Surprises Act (NSA) was designed with a noble, singular purpose: to shield American patients from the financial ruin of unexpected, out-of-network medical bills. By effectively removing the patient from the middle of billing disputes between insurers and healthcare providers, the law achieved its primary objective. However, a new, comprehensive report from Georgetown University’s Center on Health Insurance Reforms (CHIR) suggests that the mechanism created to resolve these disputes—the Independent Dispute Resolution (IDR) process—has morphed into a fiscal drain, inadvertently driving up healthcare costs across the United States.
According to the Georgetown researchers, the IDR system is no longer just a referee; it has become a catalyst for inflation. With billions of dollars in excess payments and administrative overhead, the system is increasingly viewed by economists and policy experts as a subsidy for out-of-network providers, potentially negating the original cost-saving intentions of the legislation.
The Chronology: From Legislative Success to Regulatory Chaos
The journey of the No Surprises Act has been anything but smooth. After its passage in 2020, the federal government set the stage for the IDR process to commence in 2022. The intent was to establish a "baseball-style" arbitration system where both the insurer and the provider submit a final offer, and an arbiter chooses one.
A Rocky Inception (2022–2023)
The rollout was marred by immediate friction. Providers, feeling that the initial regulatory guidance favored insurers, flooded the courts with lawsuits. These legal challenges forced regulators to pause the IDR process multiple times, creating a massive backlog. Simultaneously, the volume of disputes—which federal agencies expected to be a trickle—turned into an absolute avalanche. Arbiters were overwhelmed, leading to delays that left both providers and payers frustrated.
The Escalation Phase (2024–2025)
By 2024, the system had stabilized in terms of throughput but deteriorated in terms of cost-efficiency. Data from 2025 shows an unprecedented surge. The number of disputes jumped by 77% compared to 2024, while the total dollar amounts associated with those disputes skyrocketed by 264%. This divergence indicates that the IDR process is being utilized not just for small-scale administrative errors, but as a primary strategic tool for providers to extract higher reimbursements than they could achieve through standard contract negotiations.
Supporting Data: The Anatomy of a $22.4 Billion Problem
The Georgetown report, authored by professors Jack Hoadley and Kennah Watts, quantifies the fiscal impact of the IDR system with alarming precision. Between administrative costs, legal fees, and inflated awards, the system’s total cost impact has reached approximately $22.4 billion.
The Breakdown of Costs
- Excessive Awards: $15.6 billion of the total reflects payments to providers that exceeded comparable in-network rates.
- Administrative Overhead: $4.2 billion has been swallowed by the internal costs of running the bureaucratic machinery of the IDR process.
- Arbitration Fees: $2.7 billion in fees have been paid by the participating parties to maintain the dispute resolution infrastructure.
The "Outlier" Phenomenon
Perhaps most concerning is the emergence of "outlier" awards. The NSA was originally focused on emergency services, such as anesthesiology and radiology, where patients rarely have the choice of provider. However, the data shows that high-margin specialists—specifically surgeons, assistant surgeons, and neurologists—are now the primary drivers of the most extreme awards.
In 2025, median awards for neurology and plastic surgery ranged from 24 to 30 times the Qualifying Payment Amount (QPA)—a metric established by the government to represent fair, in-network market rates. For specific procedures like breast reductions, some awards hit 80 times the Medicare rate. While surgeons and neurologists make up only about 5% of the total volume of disputes, they account for a staggering $3.8 billion in awards, highlighting a massive systemic inefficiency.
Systemic Incentives: Why the IDR Process Is Misaligned
The core of the issue, according to the report, lies in the financial incentives built into the arbitration structure. Arbiters, who act as the final authority in these disputes, are paid per case. Crucially, they receive no compensation if a dispute is deemed ineligible.
The Arbiter-Provider Loop
This creates a perverse incentive: arbiters are financially motivated to keep the volume of disputes high and to rule in favor of the filing party—usually the provider—to ensure repeat business. The Georgetown study found that arbiters with the highest provider win rates receive the largest share of total cases.
"The evidence presented here suggests that providers have a clear incentive to keep filing disputes and to ask for higher and higher amounts," Hoadley and Watts wrote. "To date, there is no evidence that there is any ceiling on the amount requested by providers that are deemed by IDR entities to be the superior offer."
Providers, for their part, argue that the QPA and Medicare rates are fundamentally flawed metrics that do not reflect the true cost of delivering complex care. They maintain that the IDR process is simply bringing compensation closer to the reality of the market. However, this defense does little to soothe the concerns of employers and insurers who are footing the bill.
The Broader Implications: A Trickle-Down Effect on Premiums
The financial strain of the IDR system is not contained within the balance sheets of insurance companies. It is actively trickling down to the consumer in the form of rising healthcare premiums.
Impact on the Private Sector
Large insurers, including UnitedHealthcare, have reported that the IDR process is directly contributing to premium increases ranging from 2% to 6% in their commercial lines of business. This sentiment is echoed by the Business Group on Health, a non-profit representing major employers, which estimates that the IDR-driven "medical trend" is inflating total health benefits costs by approximately 2% annually.
For the average American employee, this means that while the "surprise bill" at the doctor’s office has been mitigated, the "hidden bill" in the form of higher monthly payroll deductions and increased deductibles has effectively taken its place.
Official Responses and the Path Forward
The Coalition Against Surprise Medical Billing (CASMB), which represents a broad swath of the insurance and employer community, has used the Georgetown report to issue a clarion call for legislative reform. "Employers and employees are already paying the cost of IDR misuse," the group stated. "It’s time for Congress and the administration to rein in the bad actors and set real guardrails on the provider-driven waste, fraud, and abuse within IDR."
Policy Limitations
The federal government has attempted to intervene. The Trump administration finalized a rule earlier this year aimed at streamlining and centralizing the dispute resolution process. However, industry analysts and the Georgetown researchers note that this rule fails to address the underlying financial incentives that drive the excessive filings. In some cases, the new, more efficient administrative rules may actually make it easier for providers to file more claims, inadvertently worsening the volume problem.
As the data becomes increasingly clear, the pressure on Congress to revisit the No Surprises Act is mounting. The challenge for policymakers will be to preserve the patient protections that make the law successful while dismantling the perverse incentives that have turned a consumer-protection mechanism into a multi-billion dollar engine for healthcare inflation. Without significant structural reform—such as placing caps on award amounts, reforming arbiter compensation, or incentivizing settlement over arbitration—the IDR system may continue to be a primary driver of the very cost increases the original legislation sought to prevent.
